YAP-R124me2a在肝星状细胞-ECM机械力信号传导中的作用及机制
批准号:
82070620
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
钱慧
依托单位:
学科分类:
肝损伤、修复与再生
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
钱慧
中文摘要
机械力微环境在肝纤维化中的作用愈受重视。YAP介导的机械力信号传导通路是调控ECM刚度与HSCs活化相互作用的关键机制。翻译后修饰调节YAP蛋白的亚细胞定位及共转录功能,然而它们在肝纤维化中的作用未见研究。我们首次发现YAP-R124存在非对称性双甲基化修饰,HSCs活化后核内增多,更为重要的是该修饰特异性结合STAT3并影响其转录活性。STAT3是调控肝纤维化进展的重要转录因子。本课题拟以YAP-R124me2a为靶点,探讨该修饰对肝纤维化进程的影响;利用质谱分析、ChIP-seq及Biacore等探索该修饰影响YAP与STAT3结合及协同转录机制;并通过刚度梯度及3D细胞培养等探索其调控HSCs与ECM相互作用的细胞学机制。本课题将阐明YAP-R124me2a在肝纤维化中的作用及机制,初步明确纠正ECM-HSCs机械力传导失衡对肝纤维化的疗效,有望为临床治疗慢性肝病提供新的靶点与策略。
英文摘要
Mechanical microenvironment has become increasingly important in the development of hepatic fibrosis. YAP-mediated mechanotransduction pathway is a critical mechanism regulating the interaction between HSCs activation and ECM stiffness. Post-translational modifications regulate the subcellular localization and co-transcriptional function of YAP, but their roles in liver fibrosis have not been studied. For the first time, we found that YAP-R124 had an intrinsic asymmetric dimethylation modification, which increased in the nucleus after the activation of HSCs, and more importantly, this modification could specifically bind to STAT3 and affect its transcriptional activity. STAT3 is an important transcription factor that regulates the progression of liver fibrosis. In this study, YAP-R124me2a would be served as the target to explore its effect on the progression of hepatic fibrosis; Mass spectrometry, ChIP-seq and Biacore were used to investigate the mechanism of YAP binding to STAT3 and synergistic transcription, and the cytological mechanism of regulating the interaction between HSCs and ECM was explored by stiffness gradient and 3D cell culture. This study will elucidate the role and mechanism of YAP-R124me2a in hepatic fibrogenesis, preliminarily clarify the effect of correcting the mechanotransduction imbalance of HSCs-ECM on the progression of hepatic fibrosis, and hopefully provide new targets and strategies for clinical treatment of chronic liver diseases.
在本课题的支持下:我们首先明确了YAP-R124me2a的生物学功能,即该修饰促进YAP蛋白活化,在此基础上发现主要是肝星状细胞中主要是由PRMT1促进YAP-R124me2a的修饰,重要的是肝纤维化时,PRMT1主要在肝星状细胞表达且极少在其他肝脏细胞中表达,因此我们通过新的小分子抑制剂-PT1001B来抑制PRMT1在肝星状细胞中的活性,并观察其对肝纤维化的治疗作用,结果显示,小分子抑制剂可以显著抑制HSCs的活化并减轻肝脏纤维沉积,达到治疗肝纤维化的效果。比较遗憾的是,鉴于HSCs细胞对于各种亚细胞操作的保守性及难度。后期的机制探索,尤其是围绕YAP-R124me2a在其中的潜在作用未进行深入研究。我们在明确相关的上游修饰酶后,我们进一步探究YAP-R124me2a在肝脏其他疾病中的作用及机制。我们发现SOX9可以与YAP蛋白结合并促进YAP蛋白进入细胞核,重要的是二者结合的关键位点包括YAP-R124,该位点修饰YAP-R124me2a促进了SOX9与YAP蛋白的结合并介导YAP蛋白入核,基于此我们发现了YAP蛋白进入细胞核的关键分子机制及调控模式,并进一步明确了YAP-R124me2a的生物学功能:促进YAP蛋白进入细胞核以增强YAP活性。在此基础上我们进一步阐明了该机制对于肝细胞癌及其他肿瘤生长的促进作用,并明确蛋白结合抑制多肽以及突变该位点均可阻遏YAP与SOX9蛋白结合并抑制包括肝细胞癌在内的肿瘤生长。随后,我们进一步探究了YAP-R124me2a在肿瘤耐药中的作用及机制,我们发现甲硫氨酸饮食升高了肝癌等肿瘤细胞内YAP-R124me2a水平,YAP-R124me2a促进肿瘤中YAP蛋白的活性并以此上调SLC43A2表达,而SLC43A2可增加肿瘤细胞对于甲硫氨酸的摄取,以此形成了以YAP-R124me2a-SLC43A2-甲硫氨酸的肿瘤代谢正反馈环,重要的是阻断该正反馈调控环可增加肿瘤化疗及靶向治疗的敏感性。
YAP-GPX4凝聚体液—液相分离在药物性肝损伤中的作用及其干预
-
批准号:82370598
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:钱慧
-
依托单位:
假性蛋白激酶TRB3通过促进肝细胞FOXA2降解调控肝纤维化进展
-
批准号:81870419
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:钱慧
-
依托单位:
国内基金
海外基金